Pacific Biosciences Of California (PACB) Share-based Compensation Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | 8.37% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -28.31% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 8.20% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 13.19% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 4.11% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -0.59% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 17.13% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 36.49% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 3.40% |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn | -19.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.70% |
| Mar 31, 2026 | -37.14% |
| Dec 31, 2025 | -18.87% |
| Sep 30, 2025 | 45.81% |
| Jun 30, 2025 | -128.94% |
| Mar 31, 2025 | 9.21% |
| Dec 31, 2024 | 18.00% |
| Sep 30, 2024 | -58.00% |
| Jun 30, 2024 | 2.90% |
| Mar 31, 2024 | 24.31% |
| Dec 31, 2023 | -19.83% |
| Sep 30, 2023 | 58.00% |
| Jun 30, 2023 | 205.42% |
| Mar 31, 2023 | 64.51% |
| Dec 31, 2022 | 31.02% |
| Sep 30, 2022 | -4.45% |
| Jun 30, 2022 | -40.81% |
| Mar 31, 2022 | 73.05% |
| Dec 31, 2021 | 31.59% |
| Sep 20, 2021 | 124.79% |